Tuesday, October 27, 2020
News
NEWS HOME
»
PRESS RELEASES

BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR
  SocialTwist Tell-a-Friend  
   


Date: 17-09-2020 5:55PM
Source: Boehringer Ingelheim
Category: General, Science & Research, Healthcare & Biotechnology, Pharmaceutical
Location: Ingelheim, Germany & San Diego, United States

Business Wire India

  • First clinical study to evaluate novel combination blocking KRAS G12C and its activator SOS1 to potentially increase the therapeutic benefit for lung and colorectal cancer patients
  • Study is based on preclinical evidence suggesting synergistic effect of KRAS G12C and SOS1 inhibition

Boehringer Ingelheim and Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced a clinical collaboration to evaluate the combination of BI 1701963, a SOS1::pan-KRAS inhibitor blocking KRAS independent of mutation type, and MRTX849, a KRAS G12C selective inhibitor in patients with solid tumors that harbor the KRAS G12C mutation. The collaboration will investigate the potential of this combination to provide more effective and durable responses for patients with lung and colorectal cancers who currently have limited treatment options.

Preclinical data suggest that the combination of a KRAS G12C inhibitor with a SOS1::pan-KRAS inhibitor results in increased anti-tumor activity based on the complementary mechanisms of these targeted oncology agents. By shifting the equilibrium from active KRAS(ON) towards the inactive KRAS(OFF) form, SOS1::pan-KRAS inhibitors have the potential to sensitize KRAS G12C mutant tumors to covalent KRAS G12C inhibitors that bind to KRAS(OFF).

“We look forward to collaborating with Boehringer Ingelheim to test this combination in clinical trials,” said Joseph Leveque, M.D., Executive Vice President and Chief Medical Officer of Mirati Therapeutics, Inc. “This collaboration is aligned with the broad and aggressive development strategy we have for MRTX849 and brings the potential for another therapeutic option to patients with KRAS G12C mutations.”

“We are excited to partner with Mirati in our ambition to make a difference for people living with KRAS-driven cancers. Combining our SOS1::pan-KRAS inhibitor with the mutation specific G12C inhibitor could be a win-win approach enhancing the response to therapy,” said Victoria Zazulina, M.D., Global Medical Head for Oncology at Boehringer Ingelheim. “We have a comprehensive KRAS program including the first SOS1::pan-KRAS inhibitor in the clinic, BI 1701963, for which we are exploring several combinations to optimize its therapeutic benefit in broad patient populations.”

Under the terms of the non-exclusive collaboration, Mirati will be the sponsor of the trial and Boehringer Ingelheim and Mirati will jointly share the costs of and oversee clinical development for the combined therapy.

About MRTX849

MRTX849 is an investigational, orally available small molecule that is designed to potently and selectively inhibit a form of KRAS, which harbors a substitution mutation (G12C). KRAS G12C mutations are present in approximately 14% of non-small cell lung cancer (NSCLC) adenocarcinoma patients, in 3-4% of colorectal cancer patients, and in subsets of other types of cancer. Tumors characterized by KRAS G12C mutations are commonly associated with poor prognosis and resistance to therapy, and patients with these mutations have few treatment options. MRTX849 is being evaluated in a Phase 1/2 trial treating patients with molecularly identified, KRAS G12C-positive advanced solid tumors and in the first quarter of 2020, enrollment began in the registration enabling cohort in monotherapy NSCLC, colorectal cancer and pancreatic cancer.

About BI 1701963

BI 1701963 is an investigational, orally available small molecule, that is designed to bind to the catalytic domain of SOS1 preventing the interaction with KRAS(OFF) and simultaneously blocking SOS1 driven feedback. This reduces the formation of KRAS(ON) and in consequence inhibits MAPK pathway signaling in KRAS-dependent cancers. The selective inhibition of SOS1 is a therapeutic concept that could allow KRAS blockade irrespective of KRAS mutation type (pan-KRAS approach). SOS1::KRAS inhibitors exhibit activity on a broad spectrum of KRAS alleles, including all major G12D/V/C and G13D oncoproteins, as recently published by Hofmann MH, et al. in Cancer Discovery, a journal of the American Association of Cancer Research (AACR). BI 1701963 is currently being evaluated in a Phase I clinical trial in patients with advanced KRAS-mutated cancers to evaluate safety, tolerability, pharmacokinetic and pharmacodynamic properties, and preliminary efficacy of BI 1701963 alone and in combination with MEK inhibitors.

Forward Looking Statements

This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. (“Mirati”). Any statement describing Mirati’s goals, expectations, financial or other projections, intentions or beliefs, development plans and the commercial potential of Mirati’s drug development pipeline, including without limitation MRTX849, sitravatinib and MRTX1133, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to risks and uncertainties, particularly those challenges inherent in the process of discovering, developing and commercialization of new drug products that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.

Mirati’s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Mirati’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Mirati. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Mirati’s programs are described in additional detail in Mirati’s quarterly reports on Form 10-Q and annual reports on Form 10-K, which are on file with the U.S. Securities and Exchange Commission (the “SEC”) available at the SEC’s Internet site (www.sec.gov).These forward-looking statements are made as of the date of this press release, and Mirati assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Boehringer Ingelheim’s Intended Audiences Notice

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Please click on the following link for ‘Notes to Editors’:

http://www.boehringer-ingelheim.com/press-release/clinicalcollaborationwithmirati



CONTACTS :

Investor Relations and Media Contacts:

Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
reinhard.malin@boehringer-ingelheim.com

Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: +1 203-791-6672
linda.ruckel@boehringer-ingelheim.com

Sarah Soetbeer
Junior Product Communications Manager
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-183874
sarah.soetbeer@boehringer-ingelheim.com

 

Mirati Therapeutics, Inc.
Temre Johnson
Mirati Therapeutics Inc.
Director, Investor Relations & Corporate Communications
(858) 332-3562
ir@mirati.com

More Press Releases

Medihauxe Pharma Is Fully Equipped to Handle, Store and Deliver Corona Vaccine as and When It Is Made Available

Korean Manufacturing Industry Collaborates With TradeIndia to Initiate Virtual Korea Sourcing Fair 2020 (G-Fair)

NetApp Brings Optimization and Enterprise Data Services to the Cloud

UAE’s 20by2020 Initiative Brings Life-Changing Water Solution to Thousands in Cambodian Villages

Interactive Brokers Launches Innovative Sustainable Investing Tool

Power Integrations Demonstrates Continued Industry Leadership as InnoSwitch IC Sales Surpass One Billion Units

Mary Kay Appoints Wendy Wang as Chief Commercial Officer for the Asia Pacific Region

Moody's Analytics Wins ALM Product of the Year at Asia Risk Awards

26th Yiwu Fair Concludes with Success, Reaching Deals Worth Millions in Small Commodities

Training Basket: Shaping Your Present for a Brighter Future

Audible Magic Sponsors MIDiA Research Report on The Rising Power of User-Generated Content

Rimini Street UK Earns Designation as Great Place to Work-Certified™ Company in 2020, Awarded Excellence in Wellbeing Recognition and Top 20 Ranking in 2020 Best Workplaces™ In Tech

C3.ai, Microsoft, and Adobe Combine Forces to Re-invent CRM with AI

Dahua Sponsors Omdia Webinars on Next Generation Network Cameras

WNS Announces an Industry-First with Domain-led Hyperautomation

Odd Loop, a New-Age Creative Agency in Delhi is Making the Right Moves

NTTVC Publicly Announces $500 Million Fund Created in Partnership with NTT

Western Union Expands Real-Time Payout

Malawi First Lady Joins Merck Foundation First Ladies Summit via Videoconference to Discuss Healthcare Capacity and COVID-19 Response in Africa

Triton-EV Debuts 100 percent Electric Full-Service 18-Wheeler Semi Truck

Scenic Communication Successfully on-Boards New Clients Despite Market Adversity

The Future of Food With SIAL Insights And SIAL Innovation

Infrastructure Projects to Trigger a Boom in Realty Demand in Thane: Dr. Niranjan Hiranandani

Prophylaxis to COVID-19 by AFO-202 ß-Glucan Food Supplement From Japan

Accomplished Entrepreneurs of Multi-Speciality Chain of Dental Clinics in Healthcare

Lexington Soft Teams With TestYantra to Offer Comprehensive Software Testing Services and Solutions

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Another Nepalese gang of robbers busted ...
Delhi: Doctors of Govt hospitals to hold...
Campaign to improve sex ration kicked of...
Woman's headless body stuffed in sack fo...
PGIMER-Chandigarh to resume physical OPD...
Terrorist killed, another surrenders as ...
More...    
 
 Top Stories
Global Covid-19 cases top 43.3mn: J... 
Music of 'Mohobbatein' a 'treasure'... 
Faboom witnesses significant increa... 
Hafele expands its exclusive applia... 
COVID-19: Utah doctors propose rati... 
CDS Gen Bipin Rawat takes integrity... 
BJP's Khushbu Sundar detained on wa... 
Doctors, health workers at Delhi's ...